TRIPS协议与公共健康议题谈判的成果与展望——评《多哈宣言第六段的执行决议》（上）/严海(28)
86. See WTO IP/C/W/340, Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health – United States (14 March 2002), at http://www.intracen.org/worldtradenet/docs/information/dohadevagenda/trips_study_2002.pdf, (last visited Dec 10, 2005).
87. 同上文件。
88. 《建立世界贸易组织协议》第9条。
89. Paragraph 6 of the Doha Declaration on TRIPS and Public Health, Office of the United States. Trade Representative, March 2002, http://www.ustr.gov/sectors/doha-trips-graph6.PDF(last visited Dec 10, 2005).
90. Communication from the European Communities and Their Member States to the TRIPS Council Relating to Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, June 18, 2002, http://www.europa.eu.int/comm/trade/miti/intell/inte13.htm. last visited Dec, 2005.
91. 参见贺小勇：《WTO〈多哈宣言〉第6条款问题”之研析》，载《法学评论》2004年第6期，第108页。
92. 特定产品系指用于治疗严重流行性疾病的药品，特定条件系指该药品是出口到药品生产能力不足或不具备药品生产能力的国家并有防止贸易转移的措施等。
93. WTO IP/C/W/352: Paragraph 6 of Doha Declaration on the TRIPS Agreement and Public Health, Communication from the European Communities and their member States, Council for TRIPS, 20 July, 2002.
总共29页
[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] 28
[29] 上一页 下一页